Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Subscribe To Our Newsletter & Stay Updated
